Abstract | OBJECTIVES: The role of MDR1 in clinical paclitaxel resistance remains poorly characterized. This study sought to identify the incidence and significance of P-glycoprotein (P-gp) over-expression on survival, tumor response to paclitaxel and the effect of prior cytotoxic exposure on P-gp expression in patients with paired primary and recurrent ovarian cancer samples. METHODS: Retrospective survival analysis. P-gp expression was evaluated immunohistochemically with antibodies c494 and c219. RESULTS: Thirty-two patients were identified from the tumor registry. Median interval between primary and secondary surgery was 17.9 (5.7-40.9) months. Only five primary tumors (16%) demonstrated +++ staining for P-gp. First-line treatment contained paclitaxel in 17 patients (53%) and 26 patients (81%) had been exposed to P-gp exportable chemotherapy before second surgery. Only seven of the recurrent tumors (22%) were +++. Only one of seven (14% (95% CI 0-46%)) recurrent tumors with ++ or +++ staining responded to subsequent paclitaxel, while 8 of 10 (80% (CI 46-100%)) recurrent tumors with 0/+ staining responded (P = 0.025). In multivariate analysis of outcome following second surgery, response to paclitaxel (P = 0.004) and P-gp over-expression (P < 0.001) were significant predictors of survival. CONCLUSIONS: De novo strong P-gp over-expression is uncommon, appears to change little over time or with prior exposure to chemotherapy. However, P-gp over-expression is a significant prognostic factor, and at the time of disease, relapse is inversely correlated with tumor response to paclitaxel.
|
Authors | Richard T Penson, Esther Oliva, Steven J Skates, Tina Glyptis, Arlan F Fuller Jr, Annekathryn Goodman, Michael V Seiden |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 93
Issue 1
Pg. 98-106
(Apr 2004)
ISSN: 0090-8258 [Print] United States |
PMID | 15047220
(Publication Type: Journal Article)
|
Chemical References |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Antineoplastic Agents, Phytogenic
- Paclitaxel
|
Topics |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
(biosynthesis, metabolism)
- Adult
- Aged
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Female
- Humans
- Immunohistochemistry
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, metabolism)
- Ovarian Neoplasms
(drug therapy, metabolism, surgery)
- Paclitaxel
(therapeutic use)
- Retrospective Studies
- Survival Rate
|